JAKARTA - Commission VI of the DPR RI has asked the Pharmaceutical BUMN Holding with PT Bio Farma (Persero) as the parent and its subsidiaries to continue to improve access to public health services through various health service channels, especially for the lower middle class within the framework of technology 4.0.

"This has also developed in various access to health services. This is important, yesterday we also had a hearing with them. I think it is necessary to increase this access so that we no longer use methods that are only old patterns, but how can access to public health services be serve with various technological development efforts," said Deputy Chair of Commission VI DPR RI Aria Bima as quoted from Antara, Tuesday, May 24.

Aria added, Commission VI of the DPR asked Holding Bio Farma to continue implementing government work programs to control the spread of the COVID-19 virus and its variants.

"This should not be relaxed until we really see global, national, regional ones that can guarantee the presence, disappearance of the virus or people affected by the virus in each region," he said.

In addition, he asked pharmaceutical SOEs to arrange a strategic roadmap by prioritizing synergies among pharmaceutical SOE subsidiaries in order to expand market share, improve company efficiency and performance as well as state revenue.

"We want to be proud, we want to be the leader of this BUMN to move forward. It doesn't mean that private companies are not like that, but the situation is different when we need the role of the state through BUMN. At least we can become a press maker for certain drugs We hope that important medicines that are consumed by our society, state-owned pharmaceutical companies should be the leaders there," said Aria.

Pharmaceutical SOEs are also expected to pay attention to government policies related to the level of domestic components (TKDN).

Thus, later the procurement of goods and services that are more transparent and accountable can be further improved, especially in relation to the procurement of health goods.


The English, Chinese, Japanese, Arabic, and French versions are automatically generated by the AI. So there may still be inaccuracies in translating, please always see Indonesian as our main language. (system supported by DigitalSiber.id)